| Website | nabriva.com |
| Category | BioTech |
| Phone | +43 (0)1 740 93-0 |
| Employees | |
| Founded | 2001 |
| Unattributed, 10/09 HBM BioVentures Wellcome Trust GLS Ventures Novartis Venture Fund | $22M |
Nabriva Therapeutics AG operates as a biopharmaceutical company that engages in the discovery and development of antibiotics for use in community and hospital infections. The company focuses on antibiotic classes, such as pleuromutilins designed for oral and topical application; and injectable broad-spectrum anti-MRSA cephalosporins. Its products include Oral Pleuromutilins BC-3205 and BC-3781 for multi-drug resistant (MDR) pathogens, including methicillin resistant Staphylococcus aureus (MRSA), MDR Streptococcus pneumonia, and vancomycin resistant Enterococcus faecium; Topical Pleuromutilin BC-7013 for the treatment of various bacterial associated, or derived dermatological diseases; and Cephalosporins for the treatment of hospital infections. The company was formerly known as Antibiotic Research Institute and changed its name to Nabriva Therapeutics AG in February, 2006. Nabriva Therapeutics AG was founded in 2001 is based in Vienna, Austria.
